Research Article
The CIMP Phenotype in BRAF Mutant Serrated Polyps from a Prospective Colonoscopy Patient Cohort
Table 2
Correlation between polyp type, location, gender, size, BRAF V600E and KRAS mutations, CIMP, and methylation of MLH1, p16, and IGFBP7.
| | Clinical, pathological, and molecular features | All cases | BRAF mutant | KRAS mutant | CIMP-H | MLH1 methylation | p16 methylation | IGFBP7 methylation | IGFBP7 and p16 methylation |
| | All colorectal polyps | 217 | 83 (38.25%) | 51 (23.5%) | 31 (14.29%) | 8 (3.69%) | 45 (20.74%) | 74 (34.1%) | 20 (9.22%) | | Patient age (years, SD) | | | | | | | | | | Gender | | | | | | | | | | Female | 115 | 50 (43.48%) | 26 (22.61%) | 19 (16.52%) | 4 (3.48%) | 28 (24.35%) | 49 (42.61%) | 16 (13.91%) | | Male | 102 | 33 (32.35%) | 25 (24.51%) | 12 (11.76%) | 4 (3.92%) | 17 (16.67%) | 25 (24.51%) | 4 (3.92%) | | Location | | | | | | | | | | Proximal | 112 | 44 (39.29%) | 18 (16.07%) | 30 (26.79%) | 7 (6.25%) | 38 (33.93%) | 43 (38.39%) | 18 (16.07%) | | Distal | 105 | 39 (37.14%) | 33 (31.43%) | 1 (0.95%) | 1 (0.95%) | 7 (6.67%) | 31 (29.52%) | 2 (1.9%) | | Polyp type | | | | | | | | | | Serrated polyps | 154 | 82 (53.25%) | 40 (25.97%) | 30 (19.48%) | 8 (5.19%) | 35 (22.73%) | 62 (40.26%) | 19 (12.34%) | | HP | 109 | 48 (44.04%) | 35 (32.11%) | 9 (8.26%) | 1 (0.92%) | 16 (14.68%) | 35 (32.11%) | 4 (3.67%) | | GCHP | 59 | 12 (20.34%) | 30 (50.85%) | 4 (6.78%) | 0 | 7 (11.86%) | 19 (32.2%) | 2 (3.39%) | | MVHP | 50 | 36 (72%) | 5 (10%) | 5 (10%) | 1 (2%) | 9 (18%) | 16 (32%) | 2 (4%) | | TSA | 3 | 2 (66.67%) | 0 | 1 (33.33%) | 0 | 0 | 2 (66.67%) | 0 | | MP | 7 | 4 (57.14%) | 2 (28.57%) | 2 (28.57%) | 0 | 2 (28.57%) | 3 (42.86%) | 1 (14.29%) | | SSA | 35 | 28 (80%) | 3 (8.57%) | 18 (51.43%) | 7 (20%) | 17 (48.57%) | 22 (62.86%) | 14 (40%) | | Conventional adenomas | 63 | 1 (1.59%) | 11 (17.46%) | 1 (1.59%) | 0 | 10 (15.87%) | 12 (19.05%) | 1 (1.59%) | | TA | 52 | 1 (1.92%) | 4 (7.69%) | 1 (1.92%) | 0 | 6 (11.54%) | 10 (19.23%) | 1 (1.92%) | | TVA | 11 | 0 | 7 (63.64%) | 0 | 0 | 4 (36.36%) | 2 (18.18%) | 0 | | Size | | | | | | | | | | 1–5 mm | 144 | 50 (34.72%) | 37 (25.69%) | 13 (9.03%) | 3 (2.08%) | 22 (15.28%) | 44 (30.56%) | 8 (5.56%) | | >5 mm | 73 | 33 (45.21%) | 14 (19.18%) | 18 (24.66%) | 5 (6.85%) | 23 (31.51%) | 30 (41.1%) | 12 (16.44%) | | BRAF status | | | | | | | | | | BRAF mutant | 83 | — | 0 | 28 (33.73%) | 7 (8.43%) | 27 (32.53%) | 44 (53.01%) | 17 (20.48%) | | BRAF wild | 134 | — | 51 (38.06%) | 3 (2.24%) | 1 (0.75%) | 18 (13.43%) | 30 (22.39%) | 3 (2.24%) | | KRAS status | | | | | | | | | | KRAS mutant | 51 | 0 | — | 0 | 0 | 7 (13.73%) | 8 (15.69%) | 1 (1.96%) | | KRAS wild | 166 | 83 (50%) | — | 31 (18.67%) | 8 (4.82%) | 38 (22.89%) | 66 (39.76%) | 19 (11.45%) |
|
|
